Latin America's most modern women's health products plant comes on stream

16 January 2017
grunenthal-big

The opening has been announced of new women’s health products manufacturing plant, which is based in Chile, which is claimed to be the most modern facility of its kind in Latin America.

Family-owned German drugmaker Grünenthal invested $14.5 million to build the 1,150 m2 hormone plant, which is the company’s center of excellence for hormone production in Latin America.

The new facility will initially deliver high quality women’s health products to the Chilean market and – after the pending approval of the relevant regulatory authorities (ANVIMA, ANVISA and COFEPRIS) – it will also provide products for other Latin American markets, including the biggest of the region: Brazil and Mexico. With this investment Grünenthal will improve the access of more than 168 million Latin American women to high quality health products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical